Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies

Glioblastoma (GBM) inevitably recurs due to a resistance to current standard therapy. We showed that the antidiabetic drug metformin (MF) can induce the differentiation of stem-like glioma-initiating cells and suppress tumor formation through AMPK-FOXO3 activation. In this study, we design a phase I...

Full description

Bibliographic Details
Main Authors: Makoto Ohno, Chifumi Kitanaka, Yasuji Miyakita, Shota Tanaka, Yukihiko Sonoda, Kazuhiko Mishima, Eiichi Ishikawa, Masamichi Takahashi, Shunsuke Yanagisawa, Ken Ohashi, Motoo Nagane, Yoshitaka Narita
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
metformin
newly diagnosed glioblastoma
dose-escalation
phase I
temozolomide
Online Access:https://www.mdpi.com/2072-6694/14/17/4222

Internet

https://www.mdpi.com/2072-6694/14/17/4222

Similar Items